Draft:Hancock Jaffe Laboratories
Hancock Jaffe Laboratories, Inc. is a biomedical company headquartered in Irvine, California, specializing in the development and commercialization of advanced medical devices for the treatment of cardiovascular and vascular diseases.[1]
 | |
| enVVeno Medical | |
| Company type | Public |
| ISIN | US29415J1060 |
| Industry | Medical Technology |
| Founded | 1965 |
| Founder | Warren Hancock |
| Headquarters | , |
Area served | Worldwide |
Key people | |
| Products | Hancock Aortic Tissue Valve, VenoValve, enVVe |
 US$15 million (2022) | |
Number of employees | 30 (2022) |
| Parent | enVVeno Medical |
| Website | https://envveno.com/ |
History and Founding[edit]
Founded in 1997 by Warren Hancock,[2] Hancock Jaffe Laboratories emerged with a clear mission: to address unmet needs in cardiovascular medicine through the creation of cutting-edge technologies and devices.
Key Focus Areas[edit]
Hancock Jaffe Laboratories focuses its efforts on research, development, and commercialization within the realm of medical devices, with a primary emphasis on addressing cardiovascular and vascular diseases.[3] The company has garnered recognition for its pioneering work in bioprosthetic tissues and implantable medical devices.[4]
Bioprosthetic Tissues[edit]
A notable area of expertise for Hancock Jaffe is in the development of bioprosthetic tissues.[5] These biological materials serve as crucial components for the replacement or repair of damaged cardiovascular tissues, particularly in the creation of heart valves and related implants. The company's contributions to cardiac surgery and patient care have been substantial.[6]
Implantable Medical Devices[edit]
The company boasts a diverse portfolio of implantable medical devices designed to provide therapeutic solutions for cardiovascular and vascular conditions.[7] This includes the development of stents, grafts, and other specialized implants that play a pivotal role in the treatment and management of various cardiovascular diseases.[8]
Regulatory Approvals and Collaborations[edit]
Hancock Jaffe Laboratories has demonstrated a commitment to adhering to rigorous regulatory standards. Through collaboration with regulatory authorities, the company ensures that its medical devices meet stringent criteria for safety and efficacy.[9] Regulatory approvals are instrumental in facilitating the global commercialization and distribution of Hancock Jaffe's products.[10]
References[edit]
- ^ "Hancock Jaffe Labs | VentureRadar". www.ventureradar.com. Retrieved 2024-01-18.
- ^ "Warren Hancock Net Worth (2024) – wallmine.com". wallmine.com. Retrieved 2024-01-18.
- ^ https://fyra.io. "Hancock Jaffe's VenoValve FIH 2-Year Data Suggest Benefit to Treat Chronic Venous Insufficiency". Endovascular Today. Retrieved 2024-01-18.
{{cite web}}: External link in|last= - ^ "The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis Study". Yale Medicine. Retrieved 2024-01-18.
- ^ Inc, Hancock Jaffe Laboratories (2020-07-17). "Hancock Jaffe Laboratories Announces Pricing of $5.6 Million Offering". ACCESSWIRE News Room. Retrieved 2024-01-18.
{{cite web}}:|last=has generic name (help) - ^ "The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis Study". medicine.yale.edu. Retrieved 2024-01-18.
- ^ Archives, L. A. Times (1996-01-07). "Hancock Jaffe Sells Heart Valve Stake". Los Angeles Times. Retrieved 2024-01-18.
- ^ Sprung, Keri (2018-10-09). "Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute". The Texas Heart Institute. Retrieved 2024-01-18.
- ^ "Hancock Jaffe Laboratories Receives FDA Breakthrough Designation for VenoValve". Medical Product Outsourcing. Retrieved 2024-01-18.
- ^ Dropiewski, Ken (2019-02-22). "Hancock Jaffe Successfully Starts First-in-Human VenoValve Study". Cardiac Vascular News. Retrieved 2024-01-18.